Role of immunohistochemistry in lymphoma

Murine models being studied in Hodgkin's lymphoma along with CD25 (IL-2 receptor)CD22 - IgG 1 antibody (Epratuzumab) in relapsed and refractory, indolent and aggressive NHL ongoing studies evaluating use in conjunction with Rituximab in FL, with CHOP in DLBCLCD30 - Anti CD30 (SGN 30) in Hodgkin's lymphoma and CD30 positive T-cell lymphomas (ongoing phase 2 studies)CD40 - Anti CD40 (SGN 40) in recurrent B-cell NHL (ongoing phase 2 studies)CD80 - Anti CD80 (Galiximab) in relapsed and refractory FL in conjunction with Rituximab (ongoing phase 2 studies) In conclusion, judicious use of panel of antibodies in the light of characteristic cytoarchitectural features helps to recognize the characteristic immunophenotype in most of the lymphomas.